SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences’ arm enters into strategic partnership with Bioeq AG

24 Dec 2025 Evaluate

Zydus Lifesciences’ wholly owned subsidiary -- Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq AG (Bioeq), a Swiss biopharmaceutical company, for the licensing, supply and commercialization of Bioeq’s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO, an interchangeable biosimilar of Lucentis (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO has been approved by U.S. Food and Drug Administration (USFDA) on December 18, 2025. 

This transaction marks an expansion of Zydus’ U.S. biosimilar business, following its recent partnership with Formycon AG for a biosimilar of Keytruda (Pembrolizumab). Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO in the U.S. market.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


Zydus Lifesciences Share Price

891.65 -18.75 (-2.06%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×